Dicyclomine Weight-Based Dosing in Children Over 6 Months
The FDA-approved drug label explicitly contraindicates dicyclomine in infants under 6 months of age, but does not establish a safe weight-based dosing range for children above 6 months 1. The only published pediatric dosing data comes from a single research study that used 3 mg/kg/day in infants aged 3-12 weeks for infantile colic 2.
Critical Safety Considerations
FDA Position
- Dicyclomine is contraindicated in infants less than 6 months of age due to serious adverse events including respiratory symptoms (dyspnea, respiratory collapse, apnea), seizures, syncope, muscular hypotonia, coma, and death 1
- Safety and effectiveness in pediatric patients have not been established at any age 1
- The drug label provides no approved pediatric dosing recommendations for any age group
Published Research Evidence
The only weight-based pediatric dosing data available is from a 1994 study that administered 3 mg/kg/day (divided doses) to infants with severe colic 2. This translates to approximately 0.25-0.5 mg/kg per dose if given 3-4 times daily. However, this study:
- Included infants as young as 3 weeks (below the FDA contraindication threshold)
- Was conducted before current safety warnings were established
- Showed only 53-67% efficacy for colic symptoms
Clinical Recommendation
Given the lack of FDA-approved pediatric dosing, established safety concerns, and absence of proven efficacy data, dicyclomine should not be routinely used in children of any age. If absolutely necessary in children over 6 months despite these concerns, the historical research dose of approximately 0.3-0.5 mg/kg per dose represents the only published reference point, though this lacks regulatory approval or modern safety validation 2.
Key Caveats
- No maximum dose is established for pediatric patients
- Renal and hepatic function should be considered, as the drug is substantially renally excreted 1
- Risk of heat prostration in high environmental temperatures due to decreased sweating 1
- Drowsiness and blurred vision are common adverse effects 1
- Intravenous administration must be avoided due to thrombosis risk 3
The approximation of 0.3-0.5 mg/kg per dose mentioned in your question aligns with the only available research data, but this should not be interpreted as an FDA-endorsed or guideline-supported recommendation.